Vaccinex Inc. (VCNX)
Vaccinex Statistics
Share Statistics
Vaccinex has 2.68M shares outstanding. The number of shares has increased by 68.95% in one year.
| Shares Outstanding | 2.68M |
| Shares Change (YoY) | 68.95% |
| Shares Change (QoQ) | 0% |
| Owned by Institutions (%) | 0% |
| Shares Floating | 1.15M |
| Failed to Deliver (FTD) Shares | 15 |
| FTD / Avg. Volume | 0.36% |
Short Selling Information
The latest short interest is 62.11K, so undefined% of the outstanding shares have been sold short.
| Short Interest | 62.11K |
| Short % of Shares Out | n/a |
| Short % of Float | 6.65% |
| Short Ratio (days to cover) | 0.6 |
Valuation Ratios
The PE ratio is -0.21 and the forward PE ratio is -8.5. Vaccinex's PEG ratio is 0.
| PE Ratio | -0.21 |
| Forward PE | -8.5 |
| PS Ratio | 7.52 |
| Forward PS | 0 |
| PB Ratio | -1.85 |
| P/FCF Ratio | -0.25 |
| PEG Ratio | 0 |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for Vaccinex.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 0.57, with a Debt / Equity ratio of -0.11.
| Current Ratio | 0.57 |
| Quick Ratio | 0.57 |
| Debt / Equity | -0.11 |
| Debt / EBITDA | -0.01 |
| Debt / FCF | -0.01 |
| Interest Coverage | -22885 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | $15.41K |
| Profits Per Employee | $-547.32K |
| Employee Count | 37 |
| Asset Turnover | 0.16 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | 0 |
| Effective Tax Rate | 0% |
Stock Price Statistics
The stock price has increased by -91.19% in the last 52 weeks. The beta is 1.35, so Vaccinex's price volatility has been higher than the market average.
| Beta | 1.35 |
| 52-Week Price Change | -91.19% |
| 50-Day Moving Average | 0.95 |
| 200-Day Moving Average | 3.32 |
| Relative Strength Index (RSI) | 41.14 |
| Average Volume (20 Days) | 4.18K |
Income Statement
In the last 12 months, Vaccinex had revenue of 570K and earned -20.25M in profits. Earnings per share was -43.68.
| Revenue | 570K |
| Gross Profit | 570K |
| Operating Income | -22.89M |
| Net Income | -20.25M |
| EBITDA | -19.75M |
| EBIT | -19.87M |
| Earnings Per Share (EPS) | -43.68 |
Balance Sheet
The company has 1.53M in cash and 247K in debt, giving a net cash position of 1.29M.
| Cash & Cash Equivalents | 1.53M |
| Total Debt | 247K |
| Net Cash | 1.29M |
| Retained Earnings | -339.93M |
| Total Assets | 4.85M |
| Working Capital | -1.42M |
Cash Flow
In the last 12 months, operating cash flow was -17.23M and capital expenditures -67K, giving a free cash flow of -17.3M.
| Operating Cash Flow | -17.23M |
| Capital Expenditures | -67K |
| Free Cash Flow | -17.3M |
| FCF Per Share | -37.31 |
Margins
Gross margin is 100%, with operating and profit margins of -4014.91% and -3552.81%.
| Gross Margin | 100% |
| Operating Margin | -4014.91% |
| Pretax Margin | -3552.81% |
| Profit Margin | -3552.81% |
| EBITDA Margin | -3464.56% |
| EBIT Margin | -4014.91% |
| FCF Margin | -3035.26% |
Dividends & Yields
VCNX does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | n/a |
| FCF Yield | n/a |
Analyst Forecast
Currently there are no analyst rating for VCNX.
| Price Target | n/a |
| Price Target Difference | n/a |
| Analyst Consensus | n/a |
| Analyst Count | n/a |
Stock Splits
The last stock split was on Feb 20, 2024. It was a backward split with a ratio of 1:14.
| Last Split Date | Feb 20, 2024 |
| Split Type | backward |
| Split Ratio | 1:14 |
Scores
| Altman Z-Score | -115.22 |
| Piotroski F-Score | 4 |